Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cloudbreak Therapeutics LLC operates within the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action under review. This matter is assigned to 1 distinct examiner, which points to a streamlined prosecution process. For the company, this means that its current intellectual property focus is directed toward a specific set of claims.
The busiest examiner for Cloudbreak Therapeutics LLC is HUANG, GIGI GEORGIANA, who handles 1 busiest examiner pending office action. As there is 1 pending office action in the portfolio, HUANG, GIGI GEORGIANA is the primary contact at the patent office. Practitioners can benefit from this by tailoring their communication and arguments to the specific style of this 1 distinct examiner.
The portfolio's activity is concentrated in 1 distinct art unit. This suggests that the technical scope of the current filing is well-defined within the biotechnology sector. Success in the 1 pending office action will depend on meeting the specific criteria of the 1 distinct art unit. The 1 busiest examiner pending action represents the current milestone for the company's patent strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18307449 | EMULSION FORMULATIONS OF MULTIKINASE INHIBITORS | HUANG, GIGI GEORGIANA | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18307449 | EMULSION FORMULATIONS OF MULTIKINASE INHIBITORS | HUANG, GIGI GEORGIANA | 1613 | §103 | Final Rejection | — | Pending | Apr 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCloudbreak Therapeutics LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Gigi Georgiana Huang has the most, with 1 of Cloudbreak Therapeutics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
